Sugi Predict

Sugi Predict / Compounds / SCHEMBL1108482

SCHEMBL1108482

SCHEMBL1108482

CCCCc1ncc(F)cn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ APLNR P35414 1/20 0.47
▸ HRH3 Q9Y5N1 1/20 0.36
▸ L3MBTL1 Q9Y468 3/20 0.34
▸ NFKB1 P19838 2/20 0.34
▸ TDP1 Q9NUW8 2/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ PKM P14618 1/20 0.34
▸ ALOX15 P16050 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ THPO P40225 1/20 0.34
▸ BLM P54132 1/20 0.34
▸ PMP22 Q01453 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ HIF1A Q16665 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19425636 0.86 APLNR (0.50) APLNRPKMNPC1RAB9ASMN1; SMN2
SCHEMBL19185580 0.79 NOS2 (0.38) HRH3L3MBTL1NFKB1TDP1KDM4E
SCHEMBL23148731 0.77 RAB9A (0.43) HRH3L3MBTL1NFKB1TDP1KDM4E
SCHEMBL10584256 0.77 TYR (0.39) HRH3L3MBTL1NFKB1TDP1KDM4E
SCHEMBL11197375 0.77 NPC1 (0.46) HRH3L3MBTL1NFKB1TDP1KDM4E
SCHEMBL27856885 0.77 KDM4E (0.47) HRH3L3MBTL1NFKB1TDP1KDM4E
SCHEMBL1331996 0.77 APLNR (0.47) APLNR
SCHEMBL20200849 0.77 APLNR (0.43) APLNRKDM4EALDH1A1ALOX15MAPK1
SCHEMBL7769252 0.76 APLNR (0.46) APLNRHRH3
SCHEMBL2188900 0.75 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11814391-B2 Macrocyclic compounds for the treatment of medical disorders ACHILLION PHARMACEUTICALS, INC. (US) 2023-11-14 — — US disclosed
US-8153673-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2012-04-10 — — US disclosed
US-8153673-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2012-04-10 — — US disclosed
US-20110003853-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2011-01-06 — — US disclosed
US-20110003853-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2011-01-06 — — US disclosed
EP-1676846-B1 Hydantoin derivatives as MMP inhibitors ASTRAZENECA AB (SE) 2010-12-29 — — EP disclosed
US-20100273849-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2010-10-28 — — US disclosed
US-20100273849-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2010-10-28 — — US disclosed
US-7754750-B2 a -5 substituted 1-H,3-H-imidazolidine-2,4-dione such as 5-(2-{[4-(4'-fluoro[1,1'-biphenyl]-4-yl)-1-piperazinyl]sulfonyl}ethyl)-2,4-imidazolidinedione; protease inhibitors, especially metalloelastase (MMP12) ASTRAZENECA AB (SE) 2010-07-13 — — US disclosed
US-7754750-B2 a -5 substituted 1-H,3-H-imidazolidine-2,4-dione such as 5-(2-{[4-(4'-fluoro[1,1'-biphenyl]-4-yl)-1-piperazinyl]sulfonyl}ethyl)-2,4-imidazolidinedione; protease inhibitors, especially metalloelastase (MMP12) ASTRAZENECA AB (SE) 2010-07-13 — — US disclosed
US-7427631-B2 especially as inhibitors of MMP12 ASTRAZENECA AB (SE) 2008-09-23 — — US disclosed
US-20080171882-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2008-07-17 — — US disclosed
US-7368465-B2 Respiratory system disorders; antiarthritic agents; anticancer agents; bone disorders ASTRAZENECA AB (SE) 2008-05-06 — — US disclosed
US-7368465-B2 Respiratory system disorders; antiarthritic agents; anticancer agents; bone disorders ASTRAZENECA AB (SE) 2008-05-06 — — US disclosed
US-7354940-B2 2,5-dioxoimidazolidin-4-yl acetamines and analogues as inhibitors of metalloproteinase mmp12 ASTRAZENECA AB (SE) 2008-04-08 — — US disclosed
US-7354940-B2 2,5-dioxoimidazolidin-4-yl acetamines and analogues as inhibitors of metalloproteinase mmp12 ASTRAZENECA AB (SE) 2008-04-08 — — US disclosed
US-20040138276-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-15 — — US disclosed
US-20040138276-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-15 — — US disclosed
WO-2004024060-A2 METALLOPROTEINASE INHIBITORS AND INTERMEDIATES FOR PREPARATION THEREOF ASTRAZENECA AB (SE) 2004-03-25 — — WO disclosed
WO-2004020415-A1 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. ASTRAZENECA AB (SE) 2004-03-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003853-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP14 APLNR 4328/4885HRH3 3361/4885L3MBTL1 4250/4885
US-20100273849-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP11 APLNR 802/4885HRH3 1728/4885L3MBTL1 3282/4885
US-20080171882-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP14 APLNR 4328/4885HRH3 3361/4885L3MBTL1 4250/4885
US-20040138276-A1 Metalloproteinase inhibitors MMP9, MMP11, MMP7 APLNR 923/4885HRH3 2415/4885L3MBTL1 2770/4885
US-11814391-B2 Macrocyclic compounds for the treatment of medical disorders CFD, TFPI, CFH APLNR 313/4885HRH3 948/4885L3MBTL1 4447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.